One of the key questions in the myeloma community is should we take a three drug approach for all patients with early relapse. There are certainly scientific and clinical arguments to support it, says medical oncologist Sagar Lonial from the Emory University School of Medicine, but the one missing piece of information is that we don’t have all the data that shows improvement in survival yet.